342 related articles for article (PubMed ID: 28821931)
1. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [
Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeling of monoclonal anti-CD105 with (177)Lu for potential use in radioimmunotherapy.
Lee SY; Hong YD; Felipe PM; Pyun MS; Choi SJ
Appl Radiat Isot; 2009; 67(7-8):1366-9. PubMed ID: 19324561
[TBL] [Abstract][Full Text] [Related]
4. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
8.
Ehlerding EB; Ferreira CA; Aluicio-Sarduy E; Jiang D; Lee HJ; Theuer CP; Engle JW; Cai W
Mol Pharm; 2018 Jul; 15(7):2606-2613. PubMed ID: 29787283
[TBL] [Abstract][Full Text] [Related]
9. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
10. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
11. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
13. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
15. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.
Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138
[TBL] [Abstract][Full Text] [Related]
18. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
19. Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
Ju CH; Jeong JM; Lee YS; Kim YJ; Lee BC; Lee DS; Chung JK; Lee MC; Jeong SY
Cancer Biother Radiopharm; 2010 Dec; 25(6):687-91. PubMed ID: 21204763
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Characterization of the
Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
